

James B Whitney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8940023/publications.pdf>

Version: 2024-02-01

39
papers

2,335
citations

489802

18
h-index

325983

40
g-index

43
all docs

43
docs citations

43
times ranked

4285
citing authors

#	ARTICLE	IF	CITATIONS
1	Models of SIV rebound after treatment interruption that involve multiple reactivation events. PLoS Computational Biology, 2020, 16, e1008241.	1.5	3
2	Cervico-Vaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV Immunogens. Frontiers in Immunology, 2020, 11, 1935.	2.2	3
3	A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques. Science Translational Medicine, 2020, 12, .	5.8	21
4	Microbial Dysbiosis During Simian Immunodeficiency Virus Infection is Partially Reverted with Combination Anti-retroviral Therapy. Scientific Reports, 2020, 10, 6387.	1.6	11
5	Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection. Journal of Clinical Investigation, 2020, 130, 6429-6442.	3.9	7
6	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Science Translational Medicine, 2018, 10, .	5.8	133
7	Zika virus research models. Virus Research, 2018, 254, 15-20.	1.1	9
8	Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nature Communications, 2018, 9, 5429.	5.8	49
9	Evidence that CD32a does not mark the HIV-1 latent reservoir. Nature, 2018, 561, E20-E28.	13.7	43
10	Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques. PLoS ONE, 2018, 13, e0202997.	1.1	11
11	The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. Blood Advances, 2018, 2, 76-84.	2.5	78
12	In Vitro and In Vivo Models of HIV Latency. Advances in Experimental Medicine and Biology, 2018, 1075, 241-263.	0.8	19
13	T cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection. Immunology, 2018, 155, 458-466.	2.0	1
14	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	5.8	106
15	Mauritian cynomolgus macaques with M3M4 MHC genotype control SIVmac251 infection. Journal of Medical Primatology, 2017, 46, 137-143.	0.3	10
16	Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8847-8852.	3.3	89
17	Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development. Journal of Infectious Diseases, 2017, 216, S928-S934.	1.9	49
18	Natural and cross-inducible anti-SIV antibodies in Mauritian cynomolgus macaques. PLoS ONE, 2017, 12, e0186079.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Galidesivir, a Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged with Zika Virus. <i>Open Forum Infectious Diseases</i> , 2017, 4, S55-S55.	0.4	13
20	BCX4430, a Broad-Spectrum Adenosine Analog Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged With Zika Virus. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	5
21	A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. <i>PLoS Pathogens</i> , 2016, 12, e1005545.	2.1	142
22	Zika viral dynamics and shedding in rhesus and cynomolgus macaques. <i>Nature Medicine</i> , 2016, 22, 1448-1455.	15.2	270
23	Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. <i>PLoS Pathogens</i> , 2016, 12, e1005431.	2.1	18
24	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
25	Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks. <i>Journal of Virology</i> , 2015, 89, 1965-1974.	1.5	28
26	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , 2014, 512, 74-77.	13.7	527
27	Prior exposure to an attenuated <i>Listeria</i> vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a <i>Listeria</i> vaccine in the induction of immune responses against HIV. <i>Journal of Immune Based Therapies and Vaccines</i> , 2011, 9, 2.	2.4	12
28	Genital Tract Sequestration of SIV following Acute Infection. <i>PLoS Pathogens</i> , 2011, 7, e1001293.	2.1	18
29	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. <i>Science Translational Medicine</i> , 2011, 3, 81ra36.	5.8	179
30	Serpin Induced Antiviral Activity of Prostaglandin Synthetase-2 against HIV-1 Replication. <i>PLoS ONE</i> , 2011, 6, e18589.	1.1	37
31	Evolutionary mechanisms of retroviral persistence. <i>AIDS Reviews</i> , 2011, 13, 234-9.	0.5	7
32	Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/maaque model. <i>Aids</i> , 2009, 23, 1453-1460.	1.0	13
33	T-Cell Vaccination Reduces Simian Immunodeficiency Virus Levels in Semen. <i>Journal of Virology</i> , 2009, 83, 10840-10843.	1.5	14
34	Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome. <i>Retrovirology</i> , 2007, 4, 44.	0.9	3
35	Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239. <i>Retrovirology</i> , 2006, 3, 96.	0.9	14
36	The M184V Mutation in Reverse Transcriptase Can Delay Reversion of Attenuated Variants of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2002, 76, 8958-8962.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Novel, Live Attenuated Simian Immunodeficiency Virus Constructs Containing Major Deletions in Leader RNA Sequences. <i>Journal of Virology</i> , 2001, 75, 2776-2785.	1.5	18
38	Partial Restoration of Replication of Simian Immunodeficiency Virus by Point Mutations in either the Dimerization Initiation Site (DIS) or Gag Region after Deletion Mutagenesis within the DIS. <i>Journal of Virology</i> , 2001, 75, 11920-11923.	1.5	5
39	Leader Sequences Downstream of the Primer Binding Site Are Important for Efficient Replication of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2000, 74, 8854-8860.	1.5	28